Press release
AbboMax Introduces Antibody Panels for Bcell and Tcell Lymphoma
AbboMax has developed the panels of antibodies to study lymphoma. Lymphoma is a malignant transformation of either B or T cells or their subtypes. The B-cell lymphomas are types of lymphoma affecting B cells. T-cell lymphomas are lymphomas that affect T cells. AbboMax, Inc. has been developing & manufacturing immunoassay reagents for many years in California. It specializes in high-quality services and products focusing on antibody and assay development, including polyclonal, phosphospecific antibodies, IHC grade monoclonal antibodies.San Jose, California, United States., July 31, 2019 -- AbboMax, Inc has developed the panels of antibodies to study B- and T-cell lymphomas. Lymphoma is a cancer of the lymphatic system, it is a group of cancers that develop from lymphocytes.
The lymphatic system includes the lymph nodes, spleen, thymus gland and bone marrow. There are many subtypes of lymphomas. All lymphoma subtypes combined are the seventh most common cancer in the United States. The two main categories of lymphomas are Hodgkin’s lymphomas (HL) and the non-Hodgkin’s lymphomas (NHL). Lymphoma is a malignant transformation of either B or T cells or their subtypes.
The B-cell lymphomas are types of lymphoma affecting B cells. T-cell lymphomas are lymphomas that affect T cells.
B-Cell lymphoma panel includes antibodies against:
CD19, CD20, CD22, CD45, CD45RO, CD79a, CD10, Bcl-2, Bcl-2a, Bcl-6.
T-Cell lymphoma panel includes antibodies against:
CD2, CD3, CD3zeta, CD4, CD5, CD7, CD8, CD8a, CD10, CD45, CD45RO.
Lymphoma related:
MHCII (HLA-DP and DR), CD40, CD56, CXCR3, Cyclin D1, Bcl-10, Bcl-w, Bcl-X.
About AbboMax:
AbboMax, Inc. has been developing & manufacturing high performance immunoassay reagents for many years in California. It specializes in high-quality services and products focusing on antibody and assay development, including polyclonal, phosphospecific antibodies, IHC grade monoclonal antibodies, FFPE cell pellets slides, tissue/cell blocks and CRO services.
Please explore more information at: www.abbomax.com
Contact us: info@abbomax.com Tel: 408-573-1898 Fax: 408-573-1858 San Jose, California
By Natasha Raysberg, Ph.D.
Contact:
Natasha Raysberg
AbboMax
2528 Qume Dr #8,
San Jose, CA 95131, USA
1 408-573-1898
sales@abbomax.com
http://www.abbomax.com
AbboMax, Inc. has been developing & manufacturing high performance immunoassay reagents for many years in California. It specializes in high-quality services and products focusing on antibody and assay development, including polyclonal, phosphospecific antibodies, IHC grade monoclonal antibodies, FFPE cell pellets slides, tissue/cell blocks and CRO services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AbboMax Introduces Antibody Panels for Bcell and Tcell Lymphoma here
News-ID: 1816962 • Views: …
More Releases for CD4
Idiopathic CD4+ Lymphocytopenia Market: Trends, Demand, Forecast with CAGR of 7. …
According to a new report published by CoherentMI The idiopathic CD4+ lymphocytopenia market is estimated to be valued at USD 120.7 Mn in 2024 and is expected to reach USD 204.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
Most recent Report, named "Idiopathic CD4+ Lymphocytopenia Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI offers a complete…
Idiopathic CD4+ Lymphocytopenia Market: Key Players and Competitive Landscape Se …
The idiopathic CD4+ lymphocytopenia market is estimated to be valued at USD 120.7 Mn in 2024 and is expected to reach USD 204.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.8% from 2024 to 2031.
Latest Report, titled "Idiopathic CD4+ Lymphocytopenia Market" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by CoherentMI offers a comprehensive analysis of the industry, which comprises insights on the market analysis.…
Global CD4 (Antibody) Market - Opportunities & Forecasts, 2020-2029
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global cd4 (antibody) market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able to identify the…
T Cell Surface Glycoprotein CD4 Market Witness Stunning Growth By 2028 | Biotest …
T Cell Surface Glycoprotein CD4 Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report answers questions on the current and future technological advancements and development. It delivers an analysis of main manufactures and geographic regions.
The global T Cell Surface Glycoprotein CD4 market is segmented by company, region (country), type, application, players, stakeholders, and others. The report includes the opportunities and encounters…
T Cell Surface Glycoprotein CD4 Market Pegged for Robust Expansion by 2027 | San …
With the help of this extensive market research, key players can easily achieve a prominent position in the industry. It also shows the global implications of COVID-19 on different sectors and countries as well as how it has created havoc in the entire county by bringing down the economy of every sector. In addition, this research illuminates a few crucial areas that will impact the all-inclusive market's liquidity position. It…
Idiopathic CD4+ Lymphocytopenia Market 2021-28 Healthcare Need and Demand with N …
Idiopathic CD4+ T cell lymphocytopenia (ICL) is a rare and heterogeneous clinical syndrome that is defined by persistent CD4+ T cell lymphopenia in the absence of infection with human immunodeficiency virus (HIV)-1 or any other cause of immunodeficiency.
ICL is a heterogeneous cellular immune deficiency condition, of unknown aetiology, diagnosed typically in middle age, usually after an opportunistic infection and characterized by a low CD4 cell count that is unexplained by…
